Qiaolin X Deng from Eagleville, PA, age 59

Us Patents

Cetp Inhibitors
view source
US Patent:

7737295, Jun 15, 2010
Filed:

Apr 8, 2005
Appl. No.:

11/578694
Inventors:

Amjad Ali - Freehold NJ, US
Joann Bohn - Woodbridge NJ, US
Qiaolin Deng - Edison NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Gayle E. Taylor - Jersey City NJ, US
Christopher F. Thompson - Clark NJ, US
Nazia Quraishi - Arlington MA, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

C07C 261/00
C07C 211/00
A01N 47/10
US Classification:

560115, 560132, 564336, 564337, 514476
Abstract:

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, Aand A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.

Cetp Inhibitors
view source
US Patent:

8193365, Jun 5, 2012
Filed:

Jun 14, 2010
Appl. No.:

12/815146
Inventors:

Amjad Ali - Freehold NJ, US
Joann Bohn - North Plainfield NJ, US
Qiaolin Deng - Edison NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Gayle Taylor - Red Bank NJ, US
Christopher Thompson - Clark NJ, US
Nazia Quraishi - Vienna VA, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

C07D 261/02
C07D 209/04
C07D 307/93
A01N 57/26
A01N 57/00
US Classification:

546348, 548490, 548240, 549462
Abstract:

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, Aand A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.

Cetp Inhibitors
view source
US Patent:

20060040999, Feb 23, 2006
Filed:

Jul 1, 2005
Appl. No.:

11/173295
Inventors:

Amjad Ali - Freehold NJ, US
Joann Napolitano - Woodbridge NJ, US
Qiaolin Deng - Edison NJ, US
Zhijian Lu - Clinton NJ, US
Peter Sinclair - Scotch Plains NJ, US
Gayle Taylor - Jersey City NJ, US
Christopher Thompson - Clark NJ, US
Nazia Quraishi - Arlington MA, US
Cameron Smith - Lawrenceville NJ, US
Julianne Hunt - Scotch Plains NJ, US
Adrian Dowst - Hoboken NJ, US
Yi-Heng Chen - Whippany NJ, US
Hong Li - Edison NJ, US
International Classification:

A61K 31/421
C07D 263/16
US Classification:

514376000, 548229000
Abstract:

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or Ris a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH—.

Niacin Receptor Agonists, Compositions Containing Such Compounds And Methods Of Treatment
view source
US Patent:

20070299101, Dec 27, 2007
Filed:

Oct 31, 2005
Appl. No.:

11/666966
Inventors:

Steven Colletti - Princeton Junction NJ, US
Richard Beresis - Matawan NJ, US
Weichun Chen - Livingston NJ, US
James Tata - Westfield NJ, US
Hong Shen - West Windsor NJ, US
Daria Marley - Hoboken NJ, US
Qiaolin Deng - Edison NJ, US
Jessica Frie - Princeton NJ, US
International Classification:

A61K 31/47
A61K 31/195
A61K 31/403
A61K 31/41
A61P 3/10
C07C 233/64
C07D 215/02
C07D 257/04
C07D 487/00
C07D 513/00
C07D 471/02
C07D 217/00
C07D 209/56
A61P 9/00
A61K 31/425
A61K 31/428
A61K 31/437
US Classification:

514292000, 514307000, 514312000, 514366000, 514381000, 514406000, 514411000, 514563000, 514616000, 546146000, 546153000, 546086000, 548151000, 548250000, 548359100, 548449000, 564155000, 564180000
Abstract:

The present invention relates to niacin receptor agonists of formula: (I); as well as pharmaceutically acceptable salts and solvates. The compounds are useful for treating dyslipidemias, and in particular, reducing serum LDL, VLDL and triglycerides, and raising HDL levels. Pharmaceutical compositions and methods of treatment are also included.

Cetp Inhibitors
view source
US Patent:

20080119476, May 22, 2008
Filed:

Jul 1, 2005
Appl. No.:

11/631821
Inventors:

Amjad Ali - Freehold NJ, US
Joann M. Napolitano - Woodbridge NJ, US
Qiaolin Deng - Edison NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Gayle E. Taylor - Jersey City NJ, US
Christopher F. Thompson - Clark NJ, US
Nazia Quraishi - Arlington MA, US
Cameron J. Smith - Lawrenceville NJ, US
Julianne A. Hunt - Scotch Palins NJ, US
Adrian A. Dowst - Hoboken NJ, US
Yi-Heng Chen - Whippany NJ, US
Hong Li - Edison NJ, US
International Classification:

A61K 31/422
A61K 31/40
A61K 31/4166
A61K 31/427
A61K 31/4439
A61K 31/501
A61P 9/10
C07D 233/32
C07D 263/20
C07D 417/10
C07D 417/04
C07D 413/10
C07D 413/04
C07D 401/04
C07D 285/10
C07D 233/44
C07D 207/24
A61K 31/506
A61K 31/497
A61K 31/433
A61K 31/4168
A61K 31/421
US Classification:

51425205, 51425505, 514256, 514340, 514341, 514362, 514372, 514376, 514392, 514424, 514426, 544238, 544333, 544405, 5462714, 5462741, 548134, 548200, 548229, 5483235, 5483315, 548551
Abstract:

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis:In the compounds of Formula I, B or Ris a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH—.

Cetp Inhibitors
view source
US Patent:

20100099716, Apr 22, 2010
Filed:

Nov 25, 2009
Appl. No.:

12/625783
Inventors:

Amjad ALI - Freehold NJ, US
Joann M. Napolitano - Woodbridge NJ, US
Qiaolin Deng - Edison NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Gayle E. Taylor - Jersey City NJ, US
Christopher F. Thompson - Clark NJ, US
Nazia Quraishi - Arlington MA, US
Cameron J. Smith - Lawrenceville NJ, US
Julianne A. Hunt - Scotch Plains NJ, US
Adrian A. Dowst - Hoboken NJ, US
Yi-Heng Chen - Whippany NJ, US
Hong Li - Edison NJ, US
International Classification:

A61K 31/421
C07D 263/04
C07D 413/04
A61K 31/4439
A61P 9/10
US Classification:

514340, 548229, 5462714, 514376
Abstract:

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis:In the compounds of Formula I, B or Ris a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH—.

9-Substituted Amino Triazolo Quinazoline Derivatives As Adenosine Receptor Antagonists, Pharmaceutical Compositions And Their Use
view source
US Patent:

20220220117, Jul 14, 2022
Filed:

Mar 31, 2022
Appl. No.:

17/657515
Inventors:

- Rahway NJ, US
Amjad Ali - Freehold NJ, US
Jared Cumming - Winchester MA, US
Duane DeMong - Hanover MA, US
Qiaolin Deng - Edison NJ, US
Thomas H. Graham - Somerville MA, US
Elisabeth Hennessy - Weston MA, US
Andrew J. Hoover - Boston MA, US
Ping Liu - Westfield NJ, US
Kun Liu - Needham MA, US
Umar Faruk Mansoor - Hopkinton MA, US
Jianping Pan - Monmouth Junction NJ, US
Christopher W. Plummer - Cranford NJ, US
Aaron Sather - Melrose MA, US
Uma Swaminathan - Auburndale MA, US
Huijun Wang - Westfield NJ, US
Yonglian Zhang - East Brunswick NJ, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

C07D 487/04
Abstract:

In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I):and pharmaceutically acceptable salts thereof, wherein, ring A, Rand Rare as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

Insulin-Incretin Conjugates
view source
US Patent:

20230105982, Apr 6, 2023
Filed:

Jul 28, 2021
Appl. No.:

17/386958
Inventors:

- Rahway NJ, US
Chunhui Huang - Arlington MA, US
Zhiqiang Yang - Westfield NJ, US
Lin Yan - East Brunswick NJ, US
Songnian Lin - Holmdel NJ, US
Pei Huo - Millburn NJ, US
Qiaolin Deng - Edison NJ, US
Elisabetta Bianchi - Pomezia, IT
Federica Orvieto - Pomezia, IT
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 47/62
A61K 38/26
A61K 38/28
A61K 47/54
A61P 3/08
Abstract:

Insulin-incretin conjugates comprising a peptide having agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, and/or the gastric inhibitory protein (GIP) receptor conjugated to an insulin molecule having agonist activity at the insulin receptor and use of the conjugates for treatment of metabolic diseases, for example, Type 2 diabetes, are described.